Gastric cancer refers to the cancer arising from lining of stomach. It may lead to uncontrolled growth of malignant cells that originate in stomach tissue and forms a tumor in any part of the stomach. Mainly there are five types of gastric cancer namely adenocarcinoma, squamous cell cancer, lymphoma, gastrointestinal stromal tumors, neuroendocrine tumors. From all these types, adenocarcinoma types of cancer originates from the innermost lining of stomach and accounts for more than 90% of all gastric tumors. Dysphagia, frequent burping, heartburn, stomachache are some of the early stomach cancer symptoms. The drugs of gastric cancers works on extracellular and intracellular domain of HER2 receptor of stomach and continuously suppress the tumor proliferation that lead to cell stasis and death.
Get the Future Market Analysis of Gastric Cancer Drugs at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1853
The incidence of five types of gastric cancer is currently noted worldwide. These include squamous cell cancer, neuroendocrine tumors, lymphoma, adenocarcinoma, and gastrointestinal stromal tumors. Among these adenocarcinoma, which originates from the innermost lining of stomach, accounts for over 90% of all gastric tumors. According to the American Cancer Society approximately 21,600 cases of cancer were diagnosed alone in the U.S. in 2013. While the high incidence of gastric cancer makes a key driver of the market, it is also expected to gain from the launch of therapies such as Herceptin, Xeloda, and Taxotere. On the flip side, not many gastric cancer therapies or drugs are commercially available for treatment, which could inhibit the market’s growth to an extent.
Based on drug class, the global gastric cancer drugs market can be segmented into Fluorouracil, Mitomycin C, Imatinib, Sunitinib, Doxorubicin Hydrochloride, Docetaxel, and Trastuzumab. Regionally, the global market can be classified into Asia Pacific, Europe, North America, and Rest of the World. Among these nations, Asia Pacific is exhibiting highly lucrative opportunities for the companies operating in the gastric cancer drugs market. Countries such as Japan and China currently holds dominance in the global market because they demonstrate a considerably large patient base and rising willingness among patients to spend on advanced therapies.
The number of geriatric population diagnosed with gastric cancer is also quite high across China and Japan, which makes these nations quite lucrative for the market. Besides the emerging nation, the market has been witnessing attractive opportunities in North America and Europe. However, because the total number of patients diagnosed with gastric cancer is five times higher in Japan and China than any of the Western countries, Asia Pacific has proven quite lucrative for drug developers.
Some of the leading companies who would gain from the aforementioned trends are Novartis AG, F Hoffmann-La Roche, Sanofi-Aventis, Genentech, Eli Lilly and Company, Otsuka Pharmaceutical and Merck KGaA.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453